A Pilot Study of Deep Cervical Lymphatic-venous Anastomosis in the Treatment of Alzheimer's Disease

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jun 3, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new surgical technique called deep cervical lymphatic-venous anastomosis as a potential treatment for Alzheimer’s disease (AD). Alzheimer’s is a common type of dementia that affects memory and thinking. The study aims to see if this procedure can help improve the way the brain clears out harmful proteins associated with AD, which may help slow down the disease's progression. Researchers are particularly interested in whether this approach is safe and effective for patients.

To participate in the trial, you must be between 50 and 90 years old and diagnosed with mild to moderate Alzheimer’s disease. You’ll need to be able to understand and complete some assessments, and you or your family will need to give consent for participation. The trial is not yet recruiting participants, but when it starts, those who join can expect to undergo tests to evaluate their condition and may receive the surgical treatment being studied. It's important to note that individuals with other types of dementia or certain medical conditions may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • a. aged 50-90 years (\> or equal to 50 years old, \< or equal to 90 years old) were evaluated as Alzheimer's disease group according to the 2018 NIA-AA diagnostic criteria; B. signed by the patient or family informed consent; c. Patients with mild or moderate disease, 11≤MMSE≤26; d. Subjects with primary school education or above can complete the prescribed scale evaluation; The diagnosis of AD was confirmed by e.PET or cerebrospinal fluid examination
• Exclusion Criteria:
• • a. any other disease that can cause cognitive impairment (e.g., dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia, etc.), intracranial mass impairing cognition, history of traumatic brain injury, normal pressure hydrocephalus, history of clinically significant cerebrovascular disease; b. Excluding other diseases affecting the nervous system, including nervous system infection, epilepsy, and systemic diseases affecting the function of the nervous system; c. Inability to cooperate with cognitive testing; d. Presence of contraindications to MRI examination (e.g., pacemakers, stents, claustrophobia, severe psychiatric symptoms, etc.).